Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Review of guidelines regarding mesh implants.
Yang B, Zuo W, Wu J. Yang B, et al. Among authors: zuo w. Eur J Surg Oncol. 2021 Nov;47(11):2709-2710. doi: 10.1016/j.ejso.2021.07.004. Epub 2021 Jul 7. Eur J Surg Oncol. 2021. PMID: 34462142 No abstract available.
Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.
Zhang Y, Ji Y, Li J, Lei L, Wu S, Zuo W, Jia X, Wang Y, Mo M, Zhang N, Shen Z, Wu J, Shao Z, Liu G. Zhang Y, et al. Among authors: zuo w. Breast Cancer Res Treat. 2018 Apr;168(3):679-686. doi: 10.1007/s10549-018-4660-y. Epub 2018 Jan 13. Breast Cancer Res Treat. 2018. PMID: 29332135 Clinical Trial.
Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations.
Jiang YZ, Ge LP, Jin X, Fan L, He M, Liu Y, Chen L, Zuo WJ, Wu J, Liu GY, Di GH, Wang ZH, Yu KD, Shao ZM. Jiang YZ, et al. Breast Cancer Res Treat. 2021 Jan;185(2):371-380. doi: 10.1007/s10549-020-05940-8. Epub 2020 Sep 25. Breast Cancer Res Treat. 2021. PMID: 32975708 Clinical Trial.
Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial.
Liu Y, Zhu XZ, Xiao Y, Wu SY, Zuo WJ, Yu Q, Cao AY, Li JJ, Yu KD, Liu GY, Wu J, Sun T, Cui JW, Lv Z, Li HP, Zhu XY, Jiang YZ, Wang ZH, Shao ZM. Liu Y, et al. Cell Res. 2023 May;33(5):389-402. doi: 10.1038/s41422-023-00795-2. Epub 2023 Mar 27. Cell Res. 2023. PMID: 36973538 Free PMC article. Clinical Trial.
1,219 results